USA flag logo/image

An Official Website of the United States Government

Enhancing DNA vaccines using modified Bacterial Toxin A1 Subunits as adjuvants

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85329
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
AI074334
Solicitation Year:
N/A
Solicitation Topic Code:
NIAID
Solicitation Number:
N/A
Small Business Information
PROFECTUS BIOSCIENCES, INC.
6411 Beckley St BALTIMORE, MD 21224-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2010
Title: Enhancing DNA vaccines using modified Bacterial Toxin A1 Subunits as adjuvants
Agency: HHS
Contract: 2R44AI074334-02
Award Amount: $2,447,584.00
 

Abstract:

DESCRIPTION (provided by applicant): Cholera toxin (CT) and the related heat-labile enterotoxin (LT) are AB toxins with cell targeting B domains and enzymatically active A domains. The enzymatically active A1 domains of both CT (CTA1) and LT (LTA1) have de monstrated particular promise as genetic adjuvants that can enhance the immunogenicity of DNA vaccines in small and large animals and may provide necessary boosting and dose sparing effects in humans. In our Phase I efforts, we identified mutants of CTA1 a nd LTA1 with enhanced enzymatic activity in vitro and enhanced adjuvanticity in vivo. We identified a mutant of LTA1 that induced anti-HIV and anti-SIV cellular responses in mice nearly 2-fold higher than those induced by the gold-standard adjuvant IL-12 plasmid DNA (pDNA) or in vivo electroporation. In this Phase II application, we propose screen additional mutants and select a lead A1 subunit adjuvant to compare its adjuvanticity to that of IL-12 pDNA and electroporation. Using a prototype SIV DNA vacci ne, we will compare the magnitude and polyfunctionality of the T cell response in both mice and macaques. We will follow the macaque studies with a homologous SIV challenge to determine whether any of the quantitative and qualitative differences observed i n the immune response are relevant to protection. We propose to achieve these goals through the following specific aims: Aim 1: Identify a lead A1 subunit adjuvant that induces comparable or superior immune responses to SIV vaccine antigens as compared to electroporation and IL-12 pDNA; Aim 2: Characterize the anti-SIV immune responses adjuvanted by the lead A1 subunit adjuvant vs. IL-12 pDNA and electroporation in a macaque model Aim 3: Determine if administration of a SIV pDNA vaccine adjuvanted by the le ad A1 subunit provide protection from homologous SIVmac251 challenge that is superior to that provided by IL-12 pDNA and electroporation. If the lead A1 subunit genetic adjuvant proves to be superior to IL-12 pDNA in the homologous challenge model, this ad juvant will be further evaluated in a heterologous challenge model. 2 PUBLIC HEALTH RELEVANCE: The objective of this project is to develop an advanced DNA vaccine adjuvant based on a modified A1 subunit of cholera toxin or heat-labile enterotoxin wi th enhanced enzymatic activity and adjuvanticity. Such an adjuvant is needed to enhance the clinical utility of HIV DNA vaccination in humans.

Principal Investigator:

Timothy R. Fouts
4437431110
FOUTS@PROFECTUSBIOSCIENCES.COM

Business Contact:

Jeffrey Meshulam
meshulam@profectusbiosciences.com
Small Business Information at Submission:

PROFECTUS BIOSCIENCES, INC.
TECHCENTER@UMBC 1450 SOUTH ROLLING RD. BALTIMORE, MD -

EIN/Tax ID: 102057941
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No